ATRX	ATP-Dependent Helicase
BEV	Bevacizumab
BSC	Best Supportive Care
CCNU	Lomustine
CCNU/TMZ	Lomustine/Temozolomide
CDKN2A/B	Cyclin-Dependent Kinase Inhibitor 2A/B
CYB5R2	Cytochrome b5 Reductase 2
DNA	Deoxyribonucleic Acid
EGFR	Epidermal Growth Factor Receptor
F	Female
GB	Glioblastoma
Gd	Gadolinium contrast enhancer
IDH1	Isocitrate Dehydrogenase 1
Iri	Irinotecan
KPS	Karnofsky Performance Score
M	Male
meth.	MGMT Promotor hypermethylation
mfGB	Multifocal Glioblastoma
MGMT	O-6-Methylguanine-DNA-Methyltransferase
MR	Mixed Response
MRI	Magnetic Resonance Imaging
MSP	Methylation-Specific Polymerase Chain Reaction
mTMZ	Metronomic Temozolomide Scheme (“Always On”)
n.d.	Not Determined
n.r.	Not Reached
OS	Overall Survival
Pat. No.	Patient Number
PD	Progressive Disease
PDGFRA	Platelet-Derived Growth Factor Receptor A
PFS	Progression-Free Survival
PR	Partial Response
QoL	Quality of Life
reS	Relapse Surgery
reXRT	Relapse Radiotherapy
reXRT-TMZ	Relapse Radiotherapy with Concomitant and Adjuvant Temozolomide
S	Surgery
SD	Stable Disease
sGB	Solitary Glioblastoma
TMZ	Temozolomide 5/28
TMZ 7-14	Dose Dense Temozolomide Scheme (“One Week On/One Week Off”)
TMZ 21-28	Dose Dense Temozolomide Scheme (“Three Weeks On/One Week Off”)
unmeth.	No MGMT Promotor Hypermethylation
VEGF	Vascular Endothelial Growth Factor
VM26	Teniposide
XRT	Radiotherapy
XRT-TMZ	Radiotherapy with Concomitant and Adjuvant Temozolomide